Results of azacytidine (AZA) versus supportive care in myelodysplastic syndrome (MDS).*
| . | AZA . | Supportive Care . | PValue . |
|---|---|---|---|
| *Data from Silverman et al.92 | |||
| Number treated | 99 | 92 | |
| Complete remission, % | 6 | 0 | |
| Partial remission/improved, % | 10/47 | 0/7 | <0.001 |
| Median time to transformation (mos) | 22 | 12 | 0.003 |
| Median survival (mos) | 18 | 14 | 0.1 |
| . | AZA . | Supportive Care . | PValue . |
|---|---|---|---|
| *Data from Silverman et al.92 | |||
| Number treated | 99 | 92 | |
| Complete remission, % | 6 | 0 | |
| Partial remission/improved, % | 10/47 | 0/7 | <0.001 |
| Median time to transformation (mos) | 22 | 12 | 0.003 |
| Median survival (mos) | 18 | 14 | 0.1 |